Association between anti-thyroid antibodies and negative symptoms in early psychosis.


Journal

Early intervention in psychiatry
ISSN: 1751-7893
Titre abrégé: Early Interv Psychiatry
Pays: Australia
ID NLM: 101320027

Informations de publication

Date de publication:
08 2020
Historique:
received: 25 01 2019
revised: 13 07 2019
accepted: 25 08 2019
pubmed: 19 9 2019
medline: 7 2 2021
entrez: 19 9 2019
Statut: ppublish

Résumé

In the current cross-sectional study, we aimed to explore whether thyroid function or thyroid autoimmunity are associated with psychopathological symptoms and social functioning in patients with early psychosis. We hypothesized that psychopathological severity is greater in those patients with positive thyroid autoimmunity. We studied 70 outpatients with early psychosis (<3 years of illness) and 37 healthy subjects. Psychopathological symptoms (positive, negative, disorganized, excited and depressive) and social functioning were assessed. Thyroid autoimmunity (antibodies against thyroid peroxidase [TPO-Abs] and thyroglobulin [TG-Abs]) and thyroid function (thyroid-stimulating hormone [TSH] and free thyroxin [FT4]) were determined. Associations of thyroid variables and psychometric measures were assessed with Spearman's correlations. Logistic regression was performed to explore the association between psychopathological symptoms and positive anti-thyroidal antibodies while adjusting for covariates. When compared to patients without thyroid antibodies, those with positive thyroid antibodies had more negative symptoms and poorer function (P < .05). Titres of TPO-Abs were significantly correlated with negative and depressive PANSS domains and poorer functioning. TG-Abs were also associated with poorer functioning but not with psychopathological symptoms. TSH and FT4 concentrations were not associated with clinical symptoms. In the logistic regression analysis adjusted for age, gender, antipsychotic treatment, lithium, TSH and FT4 concentrations, negative symptoms were associated with thyroid autoimmunity (OR = 1.2, P = .019). Our study suggests that anti-thyroid antibodies are associated with a more severe phenotype with increased negative symptoms and poorer functioning in early psychotic patients. Since causality cannot be inferred with cross-sectional data, future longitudinal studies are needed to overcome this limitation.

Identifiants

pubmed: 31529601
doi: 10.1111/eip.12873
doi:

Substances chimiques

Autoantibodies 0
Autoantigens 0
Iron-Binding Proteins 0
Thyrotropin 9002-71-5
Thyroglobulin 9010-34-8
TPO protein, human EC 1.11.1.7
Iodide Peroxidase EC 1.11.1.8
Thyroxine Q51BO43MG4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

470-475

Subventions

Organisme : Fundació la Marató de TV3
ID : 092230
Pays : International
Organisme : Fundació la Marató de TV3
ID : 092231
Pays : International
Organisme : Health Department of the Generalitat de Catalunya
ID : SLT006/17/00012
Pays : International
Organisme : Health Department of the Generalitat de Catalunya
ID : SLT008/18/00074
Pays : International
Organisme : Instituto de Salud Carlos III
ID : PI10/01607
Pays : International

Informations de copyright

© 2019 John Wiley & Sons Australia, Ltd.

Références

Addington, D., Addington, J., & Schissel, B. (1990). A depression rating scale for schizophrenics. Schizophrenia Research, 3, 247-251. https://doi.org/10.1016/0920-9964(90)90005-R
Barbero, J. D., Garcia-Parés, G., Llorens, M., Tost, M., Cobo, J., Palao, D., & Labad, J. (2014). Thyroglobulin antibodies and risk of readmission at one year in subjects with bipolar disorder. Psychiatry Research, 219, 109-113. https://doi.org/10.1016/j.psychres.2014.05.028
Barbero, J. D., Gutiérrez-Zotes, A., Montalvo, I., Creus, M., Cabezas, Á., Solé, M., … Labad, J. (2015). Free thyroxine levels are associated with cognitive abilities in subjects with early psychosis. Schizophrenia Research, 166, 37-42. https://doi.org/10.1016/j.schres.2015.04.030
Bartalena, L., Pellegrini, L., Meschi, M., Antonangeli, L., Bogazzi, F., Dell'Osso, L., … Placidi, G. F. (1990). Evaluation of thyroid function in patients with rapid-cycling and non-rapid-cycling bipolar disorder. Psychiatry Research, 34, 13-17. https://doi.org/10.1016/0165-1781(90)90054-9
Bauer, M. S., & Whybrow, P. C. (1990). Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: A preliminary study. Archives of General Psychiatry, 47, 435-440. https://doi.org/10.1001/archpsyc.1990.01810170035006
Bender, R., & Lange, S. (2001). Adjusting for multiple testing-when and how? Journal of Clinical Epidemiology, 54(4), 343-349. https://doi.org/10.1016/s0895-4356(00)00314-0
Bičíková, M., Hampl, R., Hill, M., Řípová, D., Mohr, P., Putz, Z., & Vanuga, P. (2011). Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuroendocrinology Letters, 32, 141-147.
De Maio, M., Graham, P., Vaughan, D., Haber, L., & Madonick, S. (2015). Review of international early psychosis programmes and a model to overcome unique challenges to the treatment of early psychosis in the United States. Early Intervention in Psychiatry, 9, 1-11. https://doi.org/10.1111/eip.12132
Degner, D., Haust, M., Meller, J., Rüther, E., & Reulbach, U. (2014). Association between autoimmune thyroiditis and depressive disorder in psychiatric outpatients. European Archives of Psychiatry and Clinical Neuroscience, 265, 67-72. https://doi.org/10.1007/s00406-014-0529-1
Endicott, J., Spitzer, R. L., Fleiss, J. L., & Cohen, J. (1976). The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry, 33, 766-771. https://doi.org/10.1001/archpsyc.1976.01770060086012
Feldman, A. Z., Shrestha, R. T., & Hennessey, J. V. (2013). Neuropsychiatric manifestations of thyroid disease. Endocrinology and Metabolism Clinics of North America., 42, 453-476. https://doi.org/10.1016/j.ecl.2013.05.005
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010). International consensus study of antipsychotic dosing. The American Journal of Psychiatry, 42, 453-476. https://doi.org/10.1176/appi.ajp.2009.09060802
Haggerty, J. J., Evans, D. L., Golden, R. N., Pedersen, C. A., Simon, J. S., & Nemeroff, C. B. (1990). The presence of antithyroid antibodies in patients with affective and nonaffective psychiatric disorders. Biological Psychiatry, 27, 51-60. https://doi.org/10.1016/0006-3223(90)90019-X
Hasler, G., Drevets, W. C., Manji, H. K., & Charney, D. S. (2004). Discovering endophenotypes for major depression. Neuropsychopharmacology, 29, 1765-1781. https://doi.org/10.1038/sj.npp.1300506
Hornig, M., Amsterdam, J. D., Kamoun, M., & Goodman, D. B. P. (1999). Autoantibody disturbances in affective disorders: A function of age and gender? Journal of Affective Disorders, 55, 29-37. https://doi.org/10.1016/S0165-0327(98)00190-6
Howes, O. D., & McCutcheon, R. (2017). Inflammation and the neural diathesis-stress hypothesis of schizophrenia: A reconceptualization. Translational Psychiatry, 7, e1024. https://doi.org/10.1038/tp.2016.278
Jose, J., Nandeesha, H., Kattimani, S., Meiyappan, K., Sarkar, S., & Sivasankar, D. (2015). Association between prolactin and thyroid hormones with severity of psychopathology and suicide risk in drug free male schizophrenia. Clinica Chimica Acta, 444, 78-80. https://doi.org/10.1016/j.cca.2015.02.003
Kay, S. R., Fiszbein, A., Vital-Herne, M., & Fuentes, L. S. (1990). The positive and negative syndrome scale--Spanish adaptation. The Journal of Nervous and Mental Disease, 178, 510-517. https://doi.org/10.1097/00005053-199017880-00007
Kupka, R. W., Breunis, M. N., Knijff, E., Ruwhof, C., Nolen, W. A., & Drexhage, H. A. (2002). Immune activation, steroid resistancy and bipolar disorder. Bipolar Disorders, 4(Suppl 1), 73-74. https://doi.org/10.1034/j.1399-5618.4.s1.29.x
Labad, J. (2019). The role of cortisol and prolactin in the pathogenesis and clinical expression of psychotic disorders. Psychoneuroendocrinology, 102, 24-36. https://doi.org/10.1016/j.psyneuen.2018.11.028
Labad, J., Barbero, J. D., Gutiérrez-Zotes, A., Montalvo, I., Creus, M., Cabezas, Á., … Vilella, E. (2016). Free thyroxine levels are associated with cognitive changes in individuals with a first episode of psychosis: A prospective 1-year follow-up study. Schizophrenia Research, 171, 182-186. https://doi.org/10.1016/j.schres.2016.01.036
Lenox, R. H., Gould, T. D., & Manji, H. K. (2002). Endophenotypes in bipolar disorder. American Journal of Medical Genetics-Neuropsychiatric Genetics, 114, 391-406. https://doi.org/10.1002/ajmg.10360
Lobo, A., Perez-Echeverria, M. J., & Artal, J. (1986). Validity of the scaled version of the General Health Questionnaire (GHQ-28) in a Spanish population. Psychological Medicine, 16, 135-140.
Lucas, A., Juliá, M. T., Cantón, A., Castell, C., Casamitjana, R., Ceres, E. M., & Granada, M. L. (2010). Undiagnosed thyroid dysfunction, thyroid antibodies, and iodine excretion in a Mediterranean population. Endocrine, 38, 391-396. https://doi.org/10.1007/s12020-010-9397-2
Noda, M. (2015). Possible role of glial cells in the relationship between thyroid dysfunction and mental disorders. Frontiers in Cellular Neuroscience, 9, 194. https://doi.org/10.3389/fncel.2015.00194
Oomen, H. A. P. C., Schipperijn, A. J. M., & Drexhage, H. A. (1996). The prevalence of affective disorder and in particular of a rapid cycling of bipolar disorder in patients with abnormal thyroid function tests. Clinical Endocrinology, 45, 215-223. https://doi.org/10.1046/j.1365-2265.1996.d01-1558.x
Othman, S. S., Abdul Kadir, K., Hassan, J., Hong, G. K., Singh, B. B., & Raman, N. (1994). High prevalence of thyroid function test abnormalities in chronic schizophrenia. The Australian and New Zealand Journal of Psychiatry, 28, 620-624.
Padmos, R. C., Bekris, L., Knijff, E. M., Tiemeier, H., Kupka, R. W., Cohen, D., … Drexhage, H. A. (2004). A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biological Psychiatry, 56, 476-482. https://doi.org/10.1016/j.biopsych.2004.07.003
Pollak, T. A., Beck, K., Irani, S. R., Howes, O. D., David, A. S., & McGuire, P. K. (2016). Autoantibodies to central nervous system neuronal surface antigens: Psychiatric symptoms and psychopharmacological implications. Psychopharmacology, 233, 1605-1621. https://doi.org/10.1007/s00213-015-4156-y
Rabinowitz, J., Levine, S. Z., Garibaldi, G., Bugarski-Kirola, D., Berardo, C. G., & Kapur, S. (2012). Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. Schizophrenia Research, 137, 147-150. https://doi.org/10.1016/j.schres.2012.01.015
Santos, N. C., Costa, P., Ruano, D., MacEdo, A., Soares, M. J., Valente, J., … Palha, J. A. (2012). Revisiting thyroid hormones in schizophrenia. Journal of Thyroid Research, 2012, 569147-569115. https://doi.org/10.1155/2012/569147
Vonk, R., van der Schot, A. C., Kahn, R. S., Nolen, W. A., & Drexhage, H. A. (2007). Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biological Psychiatry, 62, 135-140. https://doi.org/10.1016/j.biopsych.2006.08.041
Wallwork, R. S., Fortgang, R., Hashimoto, R., Weinberger, D. R., & Dickinson, D. (2012). Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophrenia Research, 137, 246-250. https://doi.org/10.1016/j.schres.2012.01.031
Wehr, T. A., Sack, D. A., Rosenthal, N. E., & Cowdry, R. W. (1988). Rapid cycling affective disorder: Contributing factors and treatment responses in 51 patients. American Journal of Psychiatry, 145, 179-184. https://doi.org/10.1176/ajp.145.2.179
Wing, J. K. (1990). SCAN. Archives of General Psychiatry, 47(6), 589. https://doi.org/10.1001/archpsyc.1990.01810180089012

Auteurs

Juan D Barbero (JD)

Department of Mental Health, Parc Taulí Hospital Universitari, Institut d'Investigació Sanitària Parc Taulí (I3PT), Translational Neuroscience Unit, Universitat Autònoma de Barcelona, CIBERSAM, Sabadell, Barcelona, Spain.

Aida Palacín (A)

Department of Mental Health, Parc Taulí Hospital Universitari, Institut d'Investigació Sanitària Parc Taulí (I3PT), Translational Neuroscience Unit, Universitat Autònoma de Barcelona, CIBERSAM, Sabadell, Barcelona, Spain.

Pilar Serra (P)

Department of Mental Health, Parc Taulí Hospital Universitari, Institut d'Investigació Sanitària Parc Taulí (I3PT), Translational Neuroscience Unit, Universitat Autònoma de Barcelona, CIBERSAM, Sabadell, Barcelona, Spain.

Montse Solé (M)

Hospital Universitari Institut Pere Mata, Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, CIBERSAM, Reus, Tarragona, Spain.

Laura Ortega (L)

Nursing Department, Universitat Rovira i Vigili, Tarragona, Spain.

Ángel Cabezas (Á)

Hospital Universitari Institut Pere Mata, Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, CIBERSAM, Reus, Tarragona, Spain.

Itziar Montalvo (I)

Department of Mental Health, Parc Taulí Hospital Universitari, Institut d'Investigació Sanitària Parc Taulí (I3PT), Translational Neuroscience Unit, Universitat Autònoma de Barcelona, CIBERSAM, Sabadell, Barcelona, Spain.

Maria José Algora (MJ)

Hospital Universitari Institut Pere Mata, Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, CIBERSAM, Reus, Tarragona, Spain.

Lourdes Martorell (L)

Hospital Universitari Institut Pere Mata, Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, CIBERSAM, Reus, Tarragona, Spain.

Elisabet Vilella (E)

Hospital Universitari Institut Pere Mata, Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, CIBERSAM, Reus, Tarragona, Spain.

Vanessa Sánchez-Gistau (V)

Hospital Universitari Institut Pere Mata, Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, CIBERSAM, Reus, Tarragona, Spain.

Javier Labad (J)

Department of Mental Health, Parc Taulí Hospital Universitari, Institut d'Investigació Sanitària Parc Taulí (I3PT), Translational Neuroscience Unit, Universitat Autònoma de Barcelona, CIBERSAM, Sabadell, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH